Previous 10 | Next 10 |
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain (AIRG) +15%. CoreCivic (CXW) +14%. Renren (RENN) +13%. Losers:...
Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19 Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical t...
Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...
Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiova...
LANCER Trial expanded to include up to 20 Additional Clinical Research Centers Oakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and cl...
Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) ( "Cardiol" or the "Company" ), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardio...
High on Growth: Cannabis REITs are far-and-away the best-performing REIT sector of the past half-decade as the budding industry thrives in the murky and often contradictory regulatory framework of legalized marijuana. Joining Innovative Industrial, Power REIT, and AFC Gamma, a pair of...
Celyad Oncology (NASDAQ:CYAD) +31% raises $32.5M in private placement with Fortress Investment Group. Longeveron (NASDAQ:LGVN) +26% on FDA orphan designation to Lomecel-B Marvell Technology (NASDAQ:MRVL) +22% after third-quarter earnings beat Code Chain New Continent ...
iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...
Cardiol Therapeutics is developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company’s lead candidate CardiolRx is an ultra-pure, high concentration cannabidiol oral formulation. The US FDA has cleared the company’s IND f...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...